Prospective exploratory study to describe in CHB naive and non-naive patients, hepatitis B virus (HBV) kinetics during the first 24 weeks of treatment with telbivudine.
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Telbivudine (Primary) ; Adefovir
- Indications Hepatitis B
- Focus Pharmacodynamics
- Acronyms EBEREST
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 May 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 07 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov